AstraZeneca to buy ZS Pharma for $2.7 billion

Anglo-Swedish drugs firm AstraZeneca has unveiled plans to buy US biopharmaceutical company ZS Pharma, in a move that boosts its portfolio for treating cardiovascular and metabolic disease.

Under the terms of the acquisition, which has been unanimously approved by ZS Pharma’s board of directors, AstraZeneca will acquire all of the outstanding capital stock for $90 per share in an all-cash transaction, equal to roughly $2.7 billion.

The deal gives AstraZeneca access to potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia - a serious condition characterized by high potassium levels in the blood linked with increased mortality in patients with chronic kidney disease (CKD) and chronic heart failure (CHF).  AstraZeneca said ZS-9 complements its increasing focus on CKD and CHF, including the investigational medicine roxadustat which is currently in Phase III development for patients with anaemia associated with CKD.

ZS-9 is currently being reviewed by the US Food and Drug Administration (FDA) with an outcome expected by May 26 2016. A submission in Europe is planned by the end of this year. AstraZeneca is estimating global peak year sales of ZS-9 to exceed $1 billion.

ZS Pharma has about 200 employees across three sites in California, Texas and Colorado. It will become a wholly owned subsidiary of AstraZeneca when the deal is completed, expected by the end of 2015.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.